Search

Author/Creator Sulkowski, M. S.

1. Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Issue 1 (26th May 2013)

Authors:
Gordon, S. C.; Yoshida, E. M.; Lawitz, E. J.; Bacon, B. R.; Sulkowski, M. S.; Davis, M.; Poordad, F.; Bronowicki, J.‐P.; Esteban, R.; Sniukiene, V.; Burroughs, M. H.; Deng, W.; Dutko, F. J.; Brass, C. A.; Albrecht, J. K.; Rajender Reddy, K.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 38:Issue 1(2013)
Page Start:
16
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. All‐oral direct‐acting antiviral therapy in HCV‐advanced liver disease is effective in real‐world practice: observations through HCV‐TARGET database. Issue 1 (28th October 2016)

Authors:
Reddy, K. R.; Lim, J. K.; Kuo, A.; Di Bisceglie, A. M.; Galati, J. S.; Morelli, G.; Everson, G. T.; Kwo, P. Y.; Brown, R. S.; Sulkowski, M. S.; Akuschevich, L.; Lok, A. S.; Pockros, P. J.; Vainorius, M.; Terrault, N. A.; Nelson, D. R.; Fried, M. W.; Manns, M. P.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 45:Issue 1(2017)
Page Start:
115
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Directly observed therapy of sofosbuvir/ribavirin +/− peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C‐DOT). Issue 1 (14th August 2017)

Authors:
Solomon, S. S.; Sulkowski, M. S.; Amrose, P.; Srikrishnan, A. K.; McFall, A. M.; Ramasamy, B.; Kumar, M. S.; Anand, S.; Thomas, D. L.; Mehta, S. H.
Journal:
Journal of viral hepatitis
Issue:
Volume 25:Issue 1(2018)
Page Start:
37
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection. Issue 6 (6th February 2018)

Authors:
Sulkowski, M. S.; Feld, J. J.; Lawitz, E.; Felizarta, F.; Corregidor, A. M.; Khalid, O.; Ghalib, R.; Smith, W. B.; Van Eygen, V.; Luo, D.; Vijgen, L.; Gamil, M.; Kakuda, T. N.; Ouwerkerk‐Mahadevan, S.; Van Remoortere, P.; Beumont, M.
Journal:
Journal of viral hepatitis
Issue:
Volume 25:Issue 6(2018)
Page Start:
631
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. Issue 11 (7th October 2013)

Authors:
Afdhal, N. H.; Zeuzem, S.; Schooley, R. T.; Thomas, D. L.; Ward, J. W.; Litwin, A. H.; Razavi, H.; Castera, L.; Poynard, T.; Muir, A.; Mehta, S. H.; Dee, L.; Graham, C.; Church, D. R.; Talal, A. H.; Sulkowski, M. S.; Jacobson, I. M.
Journal:
Journal of viral hepatitis
Issue:
Volume 20:Issue 11(2013)
Page Start:
745
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. Issue 7 (28th January 2015)

Authors:
Sterling, R. K.; Kuo, A.; Rustgi, V. K.; Sulkowski, M. S.; Stewart, T. G.; Fenkel, J. M.; El‐Genaidi, H.; Mah'moud, M. A.; Abraham, G. M.; Stewart, P. W.; Akushevich, L.; Nelson, D. R.; Fried, M. W.; Di Bisceglie, A. M.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 41:Issue 7(2015)
Page Start:
671
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗